TLR9 and prostate carcinoma: Prostate cancer cells that express low or no TLR9 fail to undergo an invasive phenotype upon CPG-ODN treatment, emphasizing TLR9-specific signaling within the tumor cell as an important driver for enhancing cancer progression.